Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lipidaemia”

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT02904772
What this trial is testing

Alipogene Tiparvovec for the Treatment of LPLD Patients

Who this might be right for
LPL Deficiency
UniQure Biopharma B.V.
Post-approval studies (Phase 4)Study completedNCT00654628
What this trial is testing

Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)

Who this might be right for
Hypercholesterolemia
Organon and Co 173
Testing effectiveness (Phase 2)Study completedNCT03944109
What this trial is testing

The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia

Who this might be right for
Hyperlipidemia
Jiangsu HengRui Medicine Co., Ltd. 110
Not applicableStudy completedNCT06227819
What this trial is testing

BVA-200 vs BVA-100 Validation Study

Who this might be right for
Heart FailureHigh Blood PressureHigh Cholesterol+7 more
Daxor Corporation 62
Large-scale testing (Phase 3)Study completedNCT00484419
What this trial is testing

Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin

Who this might be right for
Type 2 DiabetesHyperlipidemia
Daiichi Sankyo 169
Not applicableStudy completedNCT06674044
What this trial is testing

Effect of SLC01B1 (rs2306283) Polymorphism on the Efficacy and Safety Profile of Atorvastatin in Pakistani Population

Who this might be right for
Hyperlipidemias
Riphah International University 100
Early research (Phase 1)Study completedNCT02634034
What this trial is testing

A Comparison Study to Evaluate the Pharmacokinetics and Safety of NK-104-CR in Healthy Adult Volunteers

Who this might be right for
Hyperlipidemia
Kowa Research Institute, Inc. 18
Large-scale testing (Phase 3)Study completedNCT00794664
What this trial is testing

Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis

Who this might be right for
HypercholesterolemiaCoronary Heart Disease
Kastle Therapeutics, LLC 58
Not applicableStudy completedNCT07123844
What this trial is testing

Pumpkin Seeds or Oil Lower Serum Triglyceride Levels in Individuals With Hyperlipidaemia

Who this might be right for
HyperlipidemiaOverweight
Kastamonu University 159
Early research (Phase 1)Active Not RecruitingNCT06783881
What this trial is testing

Single-ascending Dose Study of Kylo-12 in Healthy Subjects

Who this might be right for
Hypertriglyceridemia
Kylonova (Xiamen) Biopharma co., LTD. 50
Not applicableStudy completedNCT01138371
What this trial is testing

Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers

Who this might be right for
Familial Hypercholesterolemia
Emory University 8
Not applicableStudy completedNCT01767077
What this trial is testing

Role of Milk Fat Globule Membranes in Dairy Foods: Health Effects in Humans

Who this might be right for
Hypercholesterolemia
Uppsala University 52
Post-approval studies (Phase 4)Study completedNCT00145574
What this trial is testing

Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol

Who this might be right for
Hypercholesterolemia
Daiichi Sankyo 194
Testing effectiveness (Phase 2)Study completedNCT01576484
What this trial is testing

Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Who this might be right for
HypercholesterolemiaHeterozygous Familial Hypercholesterolemia
Regeneron Pharmaceuticals 58
Post-approval studies (Phase 4)Looking for participantsNCT07581808
What this trial is testing

Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention

Who this might be right for
HypercholesterolemiaAtherosclerotic Cardiovascular Disease (ASCVD)
University Medical Centre Ljubljana 60
Not applicableStudy completedNCT01478789
What this trial is testing

Efficacy of Plant Sterol-Fortified Dairy Product on Plasma Lipid and Plant Sterol Concentrations in Humans

Who this might be right for
Hypercholesterolemia
University of Manitoba 47
Large-scale testing (Phase 3)Ended earlyNCT03433755
What this trial is testing

Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia

Who this might be right for
Primary HypercholesterolemiaMixed Dyslipidemia
Amgen 259
Post-approval studies (Phase 4)Study completedNCT00249938
What this trial is testing

Evaluation of Combination Cholesterol Treatments in Patients With High Cholesterol.

Who this might be right for
HyperlipidemiaDyslipidemia
University of Colorado, Denver 60
Early research (Phase 1)Study completedNCT01723735
What this trial is testing

Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects

Who this might be right for
Hypercholesterolemia
Sanofi 79
Not applicableStudy completedNCT02225340
What this trial is testing

Relationships Between Plasma PCSK9 Levels, LDL-cholesterol Concentrations and Lipoprotein (a) Levels in Familial Hypercholesterolemia

Who this might be right for
Familial Hypercholesterolemia
Laval University 348
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation